A large Russian company vindicated its claim to market in Sri-Lanka of antineoplastic drugs of BIOCAD.
The conflict started this March as the Swiss F. Hoffmann-La Roche Ltd. Applied to court with a requirement to prohibit marketing of antineoplastic drugs by BIOCAD in Sri-Lanka. Argumentation included baseless allegations of violations during marketing authorization, and the absence of clinical studies.
However documents proving that the above allegations are not consistent with reality, were submitted to the court. The court, having considered arguments of parties, dismissed the claims of F. Hoffmann-La Roche.
A representative of BIOCAD filed a counter-claim in court against the competitor, seeking compensation from F. Hoffmann-La Roche. In particular, BIOCAD reported harm to health of patients in Sri-Lanka because of unfair and improper methods of the Western manufacturer.